MONTREAL, CANADA--(Marketwired - Dec. 3, 2013) - Theratechnologies Inc. (TSX:TH) is pleased to announce that it has resumed shipment of EGRIFTA™ (tesamorelin for injection) to EMD Serono in the United States today.
Moreover, Jubilant HollisterStier, the third-party contract manufacturer for tesamorelin, also informed Theratechnologies that the strike, which was initiated by employees working at its manufacturing site in Montreal, Canada, is now over.
About Theratechnologies
Theratechnologies (TSX:TH) is a biopharmaceutical company that specializes in innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on the Securities and Exchange Commission's website at www.sec.gov.
Contact Information:
NATIONAL Public Relations
514-843-2393